Area of research
Immunology · Virology
Research interest
Dr. Carrington is a senior principal scientist at the Frederick National Laboratory for Cancer Research and head of the HLA Immunogenetics Section in the Laboratory of Integrative Cancer Immunology Program. Her group studies the influence of genetic variation at loci encoding the human leukocyte antigen (HLA), killer cell immunoglobulin-like receptors (KIR), and other immune-related molecules on risk of and outcomes to infection, cancer, autoimmunity, and maternal-fetal disease. Recent studies have focused on the genetic regulation of natural killer (NK) cell activity mediated by interactions between NK cell receptors and HLA class I molecules, as well as mechanisms underlying inter-individual variation in antigen presentation.
HLA-DQB1*03:01 and risk of HBV-related HCC.
HLA class I signal peptide variation predicts strength of NKG2A<sup>+</sup> NK cell response to missing-self and risk of human disease.
Antiretroviral therapy blocks natural selection on protective and disease-susceptible HLA-B alleles in HIV-1 infection.
Sex differences in HIV-1 reservoir cell selection are linked to altered innate immune profiles
Immunopeptidomics can inform the design of mRNA vaccines for the delivery of <i>Mycobacterium tuberculosis</i> MHC class II antigens
Sex differences in HIV-1 reservoir cell selection are linked to altered innate immune profiles.
Targeting infection-specific peptides in immunopeptidomics studies for vaccine target discovery
Immunopeptidomics can inform the design of mRNA vaccines for the delivery of <i>Mycobacterium tuberculosis</i> MHC class II antigens.
Targeting infection-specific peptides in immunopeptidomics studies for vaccine target discovery.
Evasion of NKG2D-mediated cytotoxic immunity by sarbecoviruses
Impact of HLA class I functional divergence on HIV control
Impact of HLA class I functional divergence on HIV control.
Polymorphic residues in HLA-B that mediate HIV control distinctly modulate peptide interactions with both TCR and KIR molecules
Human leukocyte antigen-DQA1*04:01 and rs2040406 variants are associated with elevated risk of childhood Burkitt lymphoma.
Prediction of differential Gag versus Env responses to a mosaic HIV-1 vaccine regimen by HLA class I alleles.
Progressive transformation of the HIV-1 reservoir cell profile over two decades of antiviral therapy
HIV post-treatment controllers have distinct immunological and virological features
HIV post-treatment controllers have distinct immunological and virological features.
HLA class I signal peptide polymorphism determines the level of CD94/NKG2-HLA-E-mediated regulation of effector cell responses.
Viral and host mediators of non-suppressible HIV-1 viremia
Viral and host mediators of non-suppressible HIV-1 viremia.
Africa-specific human genetic variation near CHD1L associates with HIV-1 load
HIV-1 reservoir size after neonatal antiretroviral therapy and the potential to evaluate antiretroviral-therapy-free remission (IMPAACT P1115): a phase 1/2 proof-of-concept study
Africa-specific human genetic variation near CHD1L associates with HIV-1 load.
HLA-DP on Epithelial Cells Enables Tissue Damage by NKp44+ Natural Killer Cells in Ulcerative Colitis
Mass Spectrometric Profiling of HLA-B44 Peptidomes Provides Evidence for Tapasin-Mediated Tryptophan Editing.
Distinct frequency patterns of LILRB3 and LILRA6 allelic variants in Europeans.
Author Correction: Africa-specific human genetic variation near CHD1L associates with HIV-1 load.
Oyez, Oyez, Oyez! Saunders PM, Brooks AG, Rossjohn J.Nat Immunol. 2023 Jul;24(7):1052-1053. doi: 10.1038/s41590-023-01541-x.PMID: 37308666
T cell reactivity to the SARS-CoV-2 Omicron variant is preserved in most but not all individuals